Global Specialty Pharmaceutical

Specialty Pharmaceutical Comprehensive Study by Application (Hospitals, Specialty Pharmacies, Others (Mail Order)), Route of administration (Oral, Parenteral, Transdermal), Therapeutic area (Oncology, Inflammatory conditions, Multiple sclerosis, Growth hormone, Other diseases), Specialty drugs (High -cost, High complexity, High touch) Players and Region - Global Market Outlook to 2030

Specialty Pharmaceutical Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Specialty Pharmaceutical
Specialty pharmaceuticals are a primary asset that should be utilized in conveying the ideal medical care our social orders need. Coronavirus has greatly affected specialty and local area drug stores in the long-and present moment. Temporarily, the remaining burden and number of visits in these drug stores are relied upon to rise immensely. In the long term, the jobs of pharmacists specialists are required to grow to different administrations inside the abilities they sharpen. Specialty pharmacies are distinct from conventional pharmacy stores in coordinating numerous parts of patient care and disease management. They are intended to productively deliver drugs with unique taking care of, capacity, and distribution necessities with normalized measures that grant economies of scale. Specialty pharmacies are additionally intended to improve clinical and financial results for patients with complex, regularly ongoing, and rare conditions, with close contact and management by clinicians. Medical care experts utilized by forte specialty pharmacies give quiet instruction, help ensure suitable prescription use, promote adherence, and endeavor to keep away from superfluous expenses. As per the examination In 2018, specialty medication prescriptions developed by more than five percent, more than twice the pace of other drugs. Behind this fast development of forte, medications are various trends, for example, expanding interest for "customized" meds that treat ongoing illnesses by considering the individual inconstancy in qualities.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Specialty Pharmaceutical market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Pfizer (United States), Roche (Switzerland), Amgen (United States), AbbVie (United States), Novo Nordisk (Denmark), Johnson & Johnson (United States), Sanofi-Aventis (France), Merck (United States), Eli Lilly (United States) and Novartis (Switzerland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are 3sbio (China) and Biotech Pharma (Egypt).

Segmentation Overview
AMA Research has segmented the market of Global Specialty Pharmaceutical market by , Application (Hospitals, Specialty Pharmacies and Others (Mail Order)) and Region.



On the basis of geography, the market of Specialty Pharmaceutical has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of administration, the sub-segment i.e. Oral will boost the Specialty Pharmaceutical market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Therapeutic area, the sub-segment i.e. Oncology will boost the Specialty Pharmaceutical market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Specialty drugs , the sub-segment i.e. High -cost will boost the Specialty Pharmaceutical market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising adoption of advanced technologies

Market Growth Drivers:
Rise each year as drugmakers focus on developing drugs to treat complex, chronic conditions and Rise each year as drugmakers focus on developing drugs to treat complex, chronic conditions

Challenges:
Management of drug shortages due to the unavailability of manufactured products and source materials around the globe.

Restraints:
The high cost of the treatment and Inadequate understanding of market needs

Opportunities:
The burden of chronic disease is soaring, The prevalence of chronic diseases like cancer, diabetes is growing everywhere and Pay-for-performance is on the rise as the adoption of electronic medical records will give them the outcomes data they need to determine best medical practice

In October 2020 Summa Health, situated in Ohio, has made a claim to the specialty pharmacy infrastructure foundation that its chiefs accept would now be able to help both up close and personal and remote interactions. and In October 2020 Eight of the country's driving health frameworks and other organization suppliers of Specialty pharmacy store tolerant consideration combined today to shape The Health System Owned Specialty Pharmacy Alliance (HOSP). HOSP will zero in on pushing for the interests of incorporated claims to specialty pharmacy stores and advancing accepted procedures that empower them to convey the best patient consideration and patient results. Wellbeing Systems Join Forces to Launch Specialty Pharmacy Alliance


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Specialty Pharmaceutical Provider, Government Regulatory and Research Organizations and End-Use Industry

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Specialty Pharmacies
  • Others (Mail Order)
By Route of administration
  • Oral
  • Parenteral
  • Transdermal

By Therapeutic area
  • Oncology
  • Inflammatory conditions
  • Multiple sclerosis
  • Growth hormone
  • Other diseases

By Specialty drugs
  • High -cost
  • High complexity
  • High touch

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise each year as drugmakers focus on developing drugs to treat complex, chronic conditions
      • 3.2.2. Rise each year as drugmakers focus on developing drugs to treat complex, chronic conditions
    • 3.3. Market Challenges
      • 3.3.1. Management of drug shortages due to the unavailability of manufactured products and source materials around the globe.
    • 3.4. Market Trends
      • 3.4.1. Rising adoption of advanced technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Specialty Pharmaceutical, by Application, Route of administration, Therapeutic area, Specialty drugs and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Specialty Pharmaceutical (Value)
      • 5.2.1. Global Specialty Pharmaceutical by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Specialty Pharmacies
        • 5.2.1.3. Others (Mail Order)
      • 5.2.2. Global Specialty Pharmaceutical by: Route of administration (Value)
        • 5.2.2.1. Oral
        • 5.2.2.2. Parenteral
        • 5.2.2.3. Transdermal
      • 5.2.3. Global Specialty Pharmaceutical by: Therapeutic area (Value)
        • 5.2.3.1. Oncology
        • 5.2.3.2. Inflammatory conditions
        • 5.2.3.3. Multiple sclerosis
        • 5.2.3.4. Growth hormone
        • 5.2.3.5. Other diseases
      • 5.2.4. Global Specialty Pharmaceutical Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Specialty Pharmaceutical: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Pfizer (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Roche (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Amgen (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AbbVie (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Novo Nordisk (Denmark)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Johnson & Johnson (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi-Aventis (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Merck (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Novartis (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Specialty Pharmaceutical Sale, by Application, Route of administration, Therapeutic area, Specialty drugs and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Specialty Pharmaceutical (Value)
      • 7.2.1. Global Specialty Pharmaceutical by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Specialty Pharmacies
        • 7.2.1.3. Others (Mail Order)
      • 7.2.2. Global Specialty Pharmaceutical by: Route of administration (Value)
        • 7.2.2.1. Oral
        • 7.2.2.2. Parenteral
        • 7.2.2.3. Transdermal
      • 7.2.3. Global Specialty Pharmaceutical by: Therapeutic area (Value)
        • 7.2.3.1. Oncology
        • 7.2.3.2. Inflammatory conditions
        • 7.2.3.3. Multiple sclerosis
        • 7.2.3.4. Growth hormone
        • 7.2.3.5. Other diseases
      • 7.2.4. Global Specialty Pharmaceutical Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Specialty Pharmaceutical: by Application(USD Million)
  • Table 2. Specialty Pharmaceutical Hospitals , by Region USD Million (2018-2023)
  • Table 3. Specialty Pharmaceutical Specialty Pharmacies , by Region USD Million (2018-2023)
  • Table 4. Specialty Pharmaceutical Others (Mail Order) , by Region USD Million (2018-2023)
  • Table 5. Specialty Pharmaceutical: by Route of administration(USD Million)
  • Table 6. Specialty Pharmaceutical Oral , by Region USD Million (2018-2023)
  • Table 7. Specialty Pharmaceutical Parenteral , by Region USD Million (2018-2023)
  • Table 8. Specialty Pharmaceutical Transdermal , by Region USD Million (2018-2023)
  • Table 9. Specialty Pharmaceutical: by Therapeutic area(USD Million)
  • Table 10. Specialty Pharmaceutical Oncology , by Region USD Million (2018-2023)
  • Table 11. Specialty Pharmaceutical Inflammatory conditions , by Region USD Million (2018-2023)
  • Table 12. Specialty Pharmaceutical Multiple sclerosis , by Region USD Million (2018-2023)
  • Table 13. Specialty Pharmaceutical Growth hormone , by Region USD Million (2018-2023)
  • Table 14. Specialty Pharmaceutical Other diseases , by Region USD Million (2018-2023)
  • Table 15. South America Specialty Pharmaceutical, by Country USD Million (2018-2023)
  • Table 16. South America Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 17. South America Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 18. South America Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 19. South America Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 20. Brazil Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 21. Brazil Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 22. Brazil Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 23. Brazil Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 24. Argentina Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 25. Argentina Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 26. Argentina Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 27. Argentina Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 28. Rest of South America Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 30. Rest of South America Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 31. Rest of South America Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 32. Asia Pacific Specialty Pharmaceutical, by Country USD Million (2018-2023)
  • Table 33. Asia Pacific Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 34. Asia Pacific Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 35. Asia Pacific Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 36. Asia Pacific Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 37. China Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 38. China Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 39. China Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 40. China Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 41. Japan Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 42. Japan Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 43. Japan Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 44. Japan Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 45. India Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 46. India Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 47. India Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 48. India Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 49. South Korea Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 50. South Korea Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 51. South Korea Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 52. South Korea Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 53. Taiwan Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 54. Taiwan Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 55. Taiwan Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 56. Taiwan Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 57. Australia Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 58. Australia Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 59. Australia Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 60. Australia Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 61. Rest of Asia-Pacific Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 62. Rest of Asia-Pacific Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 63. Rest of Asia-Pacific Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 65. Europe Specialty Pharmaceutical, by Country USD Million (2018-2023)
  • Table 66. Europe Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 67. Europe Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 68. Europe Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 69. Europe Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 70. Germany Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 71. Germany Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 72. Germany Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 73. Germany Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 74. France Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 75. France Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 76. France Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 77. France Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 78. Italy Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 79. Italy Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 80. Italy Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 81. Italy Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 82. United Kingdom Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 83. United Kingdom Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 84. United Kingdom Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 85. United Kingdom Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 86. Netherlands Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 87. Netherlands Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 88. Netherlands Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 89. Netherlands Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 90. Rest of Europe Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 91. Rest of Europe Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 92. Rest of Europe Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 93. Rest of Europe Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 94. MEA Specialty Pharmaceutical, by Country USD Million (2018-2023)
  • Table 95. MEA Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 96. MEA Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 97. MEA Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 98. MEA Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 99. Middle East Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 100. Middle East Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 101. Middle East Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 102. Middle East Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 103. Africa Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 104. Africa Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 105. Africa Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 106. Africa Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 107. North America Specialty Pharmaceutical, by Country USD Million (2018-2023)
  • Table 108. North America Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 109. North America Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 110. North America Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 111. North America Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 112. United States Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 113. United States Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 114. United States Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 115. United States Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 116. Canada Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 117. Canada Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 118. Canada Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 119. Canada Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 120. Mexico Specialty Pharmaceutical, by Application USD Million (2018-2023)
  • Table 121. Mexico Specialty Pharmaceutical, by Route of administration USD Million (2018-2023)
  • Table 122. Mexico Specialty Pharmaceutical, by Therapeutic area USD Million (2018-2023)
  • Table 123. Mexico Specialty Pharmaceutical, by Specialty drugs USD Million (2018-2023)
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Specialty Pharmaceutical: by Application(USD Million)
  • Table 135. Specialty Pharmaceutical Hospitals , by Region USD Million (2025-2030)
  • Table 136. Specialty Pharmaceutical Specialty Pharmacies , by Region USD Million (2025-2030)
  • Table 137. Specialty Pharmaceutical Others (Mail Order) , by Region USD Million (2025-2030)
  • Table 138. Specialty Pharmaceutical: by Route of administration(USD Million)
  • Table 139. Specialty Pharmaceutical Oral , by Region USD Million (2025-2030)
  • Table 140. Specialty Pharmaceutical Parenteral , by Region USD Million (2025-2030)
  • Table 141. Specialty Pharmaceutical Transdermal , by Region USD Million (2025-2030)
  • Table 142. Specialty Pharmaceutical: by Therapeutic area(USD Million)
  • Table 143. Specialty Pharmaceutical Oncology , by Region USD Million (2025-2030)
  • Table 144. Specialty Pharmaceutical Inflammatory conditions , by Region USD Million (2025-2030)
  • Table 145. Specialty Pharmaceutical Multiple sclerosis , by Region USD Million (2025-2030)
  • Table 146. Specialty Pharmaceutical Growth hormone , by Region USD Million (2025-2030)
  • Table 147. Specialty Pharmaceutical Other diseases , by Region USD Million (2025-2030)
  • Table 148. South America Specialty Pharmaceutical, by Country USD Million (2025-2030)
  • Table 149. South America Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 150. South America Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 151. South America Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 152. South America Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 153. Brazil Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 154. Brazil Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 155. Brazil Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 156. Brazil Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 157. Argentina Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 158. Argentina Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 159. Argentina Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 160. Argentina Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 161. Rest of South America Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 162. Rest of South America Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 163. Rest of South America Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 164. Rest of South America Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 165. Asia Pacific Specialty Pharmaceutical, by Country USD Million (2025-2030)
  • Table 166. Asia Pacific Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 167. Asia Pacific Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 168. Asia Pacific Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 169. Asia Pacific Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 170. China Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 171. China Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 172. China Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 173. China Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 174. Japan Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 175. Japan Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 176. Japan Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 177. Japan Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 178. India Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 179. India Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 180. India Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 181. India Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 182. South Korea Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 183. South Korea Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 184. South Korea Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 185. South Korea Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 186. Taiwan Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 187. Taiwan Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 188. Taiwan Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 189. Taiwan Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 190. Australia Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 191. Australia Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 192. Australia Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 193. Australia Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 194. Rest of Asia-Pacific Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 195. Rest of Asia-Pacific Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 196. Rest of Asia-Pacific Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 197. Rest of Asia-Pacific Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 198. Europe Specialty Pharmaceutical, by Country USD Million (2025-2030)
  • Table 199. Europe Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 200. Europe Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 201. Europe Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 202. Europe Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 203. Germany Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 204. Germany Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 205. Germany Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 206. Germany Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 207. France Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 208. France Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 209. France Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 210. France Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 211. Italy Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 212. Italy Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 213. Italy Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 214. Italy Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 215. United Kingdom Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 216. United Kingdom Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 217. United Kingdom Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 218. United Kingdom Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 219. Netherlands Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 220. Netherlands Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 221. Netherlands Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 222. Netherlands Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 223. Rest of Europe Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 224. Rest of Europe Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 225. Rest of Europe Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 226. Rest of Europe Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 227. MEA Specialty Pharmaceutical, by Country USD Million (2025-2030)
  • Table 228. MEA Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 229. MEA Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 230. MEA Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 231. MEA Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 232. Middle East Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 233. Middle East Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 234. Middle East Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 235. Middle East Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 236. Africa Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 237. Africa Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 238. Africa Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 239. Africa Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 240. North America Specialty Pharmaceutical, by Country USD Million (2025-2030)
  • Table 241. North America Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 242. North America Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 243. North America Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 244. North America Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 245. United States Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 246. United States Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 247. United States Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 248. United States Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 249. Canada Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 250. Canada Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 251. Canada Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 252. Canada Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 253. Mexico Specialty Pharmaceutical, by Application USD Million (2025-2030)
  • Table 254. Mexico Specialty Pharmaceutical, by Route of administration USD Million (2025-2030)
  • Table 255. Mexico Specialty Pharmaceutical, by Therapeutic area USD Million (2025-2030)
  • Table 256. Mexico Specialty Pharmaceutical, by Specialty drugs USD Million (2025-2030)
  • Table 257. Research Programs/Design for This Report
  • Table 258. Key Data Information from Secondary Sources
  • Table 259. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Specialty Pharmaceutical: by Application USD Million (2018-2023)
  • Figure 5. Global Specialty Pharmaceutical: by Route of administration USD Million (2018-2023)
  • Figure 6. Global Specialty Pharmaceutical: by Therapeutic area USD Million (2018-2023)
  • Figure 7. South America Specialty Pharmaceutical Share (%), by Country
  • Figure 8. Asia Pacific Specialty Pharmaceutical Share (%), by Country
  • Figure 9. Europe Specialty Pharmaceutical Share (%), by Country
  • Figure 10. MEA Specialty Pharmaceutical Share (%), by Country
  • Figure 11. North America Specialty Pharmaceutical Share (%), by Country
  • Figure 12. Global Specialty Pharmaceutical share by Players 2023 (%)
  • Figure 13. Global Specialty Pharmaceutical share by Players (Top 3) 2023(%)
  • Figure 14. Global Specialty Pharmaceutical share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 17. Pfizer (United States) Revenue: by Geography 2023
  • Figure 18. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Roche (Switzerland) Revenue: by Geography 2023
  • Figure 20. Amgen (United States) Revenue, Net Income and Gross profit
  • Figure 21. Amgen (United States) Revenue: by Geography 2023
  • Figure 22. AbbVie (United States) Revenue, Net Income and Gross profit
  • Figure 23. AbbVie (United States) Revenue: by Geography 2023
  • Figure 24. Novo Nordisk (Denmark) Revenue, Net Income and Gross profit
  • Figure 25. Novo Nordisk (Denmark) Revenue: by Geography 2023
  • Figure 26. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 27. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 28. Sanofi-Aventis (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi-Aventis (France) Revenue: by Geography 2023
  • Figure 30. Merck (United States) Revenue, Net Income and Gross profit
  • Figure 31. Merck (United States) Revenue: by Geography 2023
  • Figure 32. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 34. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 35. Novartis (Switzerland) Revenue: by Geography 2023
  • Figure 36. Global Specialty Pharmaceutical: by Application USD Million (2025-2030)
  • Figure 37. Global Specialty Pharmaceutical: by Route of administration USD Million (2025-2030)
  • Figure 38. Global Specialty Pharmaceutical: by Therapeutic area USD Million (2025-2030)
  • Figure 39. South America Specialty Pharmaceutical Share (%), by Country
  • Figure 40. Asia Pacific Specialty Pharmaceutical Share (%), by Country
  • Figure 41. Europe Specialty Pharmaceutical Share (%), by Country
  • Figure 42. MEA Specialty Pharmaceutical Share (%), by Country
  • Figure 43. North America Specialty Pharmaceutical Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Pfizer (United States)
  • Roche (Switzerland)
  • Amgen (United States)
  • AbbVie (United States)
  • Novo Nordisk (Denmark)
  • Johnson & Johnson (United States)
  • Sanofi-Aventis (France)
  • Merck (United States)
  • Eli Lilly (United States)
  • Novartis (Switzerland)
Additional players considered in the study are as follows:
3sbio (China) , Biotech Pharma (Egypt)
Select User Access Type

Key Highlights of Report


Feb 2024 214 Pages 95 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Specialty Pharmaceutical Quantitative research analysis
Global Specialty Pharmaceutical Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Pfizer (United States), Roche (Switzerland), Amgen (United States), AbbVie (United States), Novo Nordisk (Denmark), Johnson & Johnson (United States), Sanofi-Aventis (France), Merck (United States), Eli Lilly (United States) and Novartis (Switzerland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising adoption of advanced technologies" is seen as one of major influencing trends for Specialty Pharmaceutical Market during projected period 2023-2030.
The Specialty Pharmaceutical market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Specialty Pharmaceutical Report?

Have a Query? Click Here

Other Related Reports

Anticoagulant Drug Comprehensive Study by Type (Coumarins & Indandiones, Factor Xa Inhibitors, Heparins, Thrombin Inhibitors), Application (Atrial Fibrillation, Deep Vein Thrombosis, Artificial Heart...
$ 3750
Neurological Disorder Drugs Comprehensive Study by Type (Antipsychotic, Antiepileptic, Anticholinergic, Analgesics, Hypnotic and Sedative, Antihypertensive, Anticoagulants, Others), Application (Hosp...
$ 3750
Glycopyrrolate Comprehensive Study by Application (Hospitals, Clinics), Form (Tablet, Solution), Sales Channel (Offline (Pharma Stores, Medical Outlets), Online (E-commerce)) Players and Region - Glo...
$ 3500
Levodopa Comprehensive Study by Application (Pharmaceuticals Industry, Dietary Supplements), Distribution Channel (Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies) Players and Region - Gl...
$ 3500
Argatroban Comprehensive Study by Type (Argatroban Powder, Argatroban Injection), Application (Heparin-induced Thrombocytopenia (HIT), Percutaneous Coronary Intervention, Cerebral Arterial Thrombosis...
$ 3450
Deferasirox Comprehensive Study by Type (Tablets, Suspension, Granules, Others), Application (Transfusional Iron Overload, Non-Transfusional Iron Overload, Others), Distribution Channel (Pharmacy Sto...
$ 3650